Replies to post #5940 on NorthWest Biotherapeutics Inc (NWBO)

[longtermthinker]

Traders delight!
Between the potential of the therapy on one side and
Linda Powers poorly written and even more poorly timed
PR, along with AF negative articles, on the other, what a
great tug of war we shall have over the next few months, I think.
I continue to be long with most of my position, but the stock
is doing wonders for my cash position on the day trading activity.

[RRRichmond]

Sir Flip, I too was concerned by the effect of chemo and radiation on NWBO's dendritic mix. After Ms. Powers comment, l felt she was expressing that the SOC was ultimately having a negative impact on the administered DCVax-L. I have found other comments that allude to this by Ms. Powers, including the possibility of DCVax, in time, replacing present day SOC. The financial implications to existing providers are substantial and threatening as well. This must be a real consideration, as the characteristics of the existing SOC are indiscriminant. As it is nearly impossible to enter into a Phase III in the GBM area without utilizing existing SOC, NWBO is in a classic Catch 22 situation.

Presently, this is my primary concern regarding results. I would appreciate a more in depth discussion of the impact of existing SOC, over time, and how it affects the charged DCVax-L from some contributor more knowlegible of the biologic interaction of the two. Do you think that this might explain the need for multiple injections?